torcetrapib
Small moleculeexperimental
Torcetrapib was a drug being developed to treat hypercholesterolemia and prevent cardiovascular disease. Its development was halted in 2006 when phase III studies showed excessive all-cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib. — Wikipedia
Clinical trial activity
14 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
14
Phase 3
14
Phase 4
0
Earliest trial started Oct 1, 2003 (NCT00134173)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
- Coronary Artery Disease · Phase 3
- Coronary Disease · Phase 3
- Diabetes Mellitus · Phase 3
- Dyslipidemias · Phase 3
- Hypercholesterolemia · Phase 3
- Hyperlipidemias · Phase 3
- Hyperlipoproteinemia Type II · Phase 3
- Hyperlipoproteinemia Type III · Phase 3
- Hyperlipoproteinemia Type IV · Phase 3
- Hypertriglyceridemia · Phase 3
Mechanism of action
- Cholesteryl ester transfer proteinINHIBITOR
CETP inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC- Mol. weight
- 600.48 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTorcetrapib ↗
- ChEMBLCHEMBL479527 ↗
Also known as
- cp529414
- cp 529414
- cp 529,414
- cp-529414
- cp-529414
- cp-529414
- cp-529,414
- cp529,414
- torcetrapib
- torcetrapib
- torcetrapib
- torcetrapib
- torcetrapib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00267280 | Phase 3 | Jan 1, 2006 | Pfizer |
| NCT00267254 | Phase 3 | Jan 1, 2006 | Pfizer |
| NCT00267267 | Phase 3 | Jan 1, 2006 | Pfizer |
| NCT00139061 | Phase 3 | Mar 1, 2005 | Pfizer |
| NCT00134485 | Phase 3 | Mar 1, 2005 | Pfizer |
| NCT00134511 | Phase 3 | Mar 1, 2005 | Pfizer |
| NCT00145431 | Phase 3 | Mar 1, 2005 | Pfizer |
| NCT00134498 | Phase 3 | Feb 1, 2005 | Pfizer |
| NCT00137462 | Phase 3 | Nov 1, 2004 | Pfizer |
| NCT00138762 | Phase 3 | Jul 1, 2004 | Pfizer |
| NCT00134264 | Phase 3 | Jul 1, 2004 | Pfizer |
| NCT00136981 | Phase 3 | Dec 1, 2003 | Pfizer |
| NCT00134238 | Phase 3 | Nov 1, 2003 | Pfizer |
| NCT00134173 | Phase 3 | Oct 1, 2003 | Pfizer |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 14 | 14 | 1 | 2003 |
1 organizations
Page 1 / 1